PIK3CA and breast cancer: In this study, we tested the pan-PI3K/mTOR inhibitor, gedatolisib, and node-selective inhibitors for PI3Kα (alpelisib), AKT (capivasertib) and mTORC1 (everolimus) to compare the functional effect of inhibiting single versus multiple PAM pathway nodes in a panel of breast cancer cell lines.